It was already a long slog for Dendreon to get its long-awaited FDA approval for prostate cancer drug Provenge, but this might be even more important.  Today, the Centers for Medicare and Medicaid Services (CMS) begins reviewing Provenge to decide how much coverage Medicare will provide for the drug, if any.

Provenge works by boosting . . . → Read More: CMS To Review Prostate Drug Provenge for Medicare Coverage Today